HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab- mediated lysis

Haematologica

Volumn 95, Issue 12, 2010, Pages 2063-2071

  van Meerten, Tom ^a   Rozemuller, Henk ^a   Hol, Samantha ^a   Moerer, Petra ^a   Zwart, Mieke ^a   Hagenbeek, Anton ^a   MacKus, Wendy J M ^b   Parren, Paul W H I ^b   van Winkel, Jan G J ^a,b   Ebeling, Saskia B ^a   Martens, Anton C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GENMAB   (Netherlands)

Author keywords

Antibody therapy; CD20; In vivo model; Ofatumumab; Rituximab

Indexed keywords

CD20 ANTIGEN; EPITOPE; HUMAB 7D8; LUCIFERASE; MONOCLONAL ANTIBODY; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; RETROVIRUS; SURVIVAL TIME; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; LEUKEMIA, EXPERIMENTAL; LUCIFERASES; LUMINESCENT MEASUREMENTS; MEMBRANE MICRODOMAINS; MICE; PROTEIN TRANSPORT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649813499     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.025783     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J,Thun MJ. Cancer statistics 2007. Cancer J Clin. 2007;57(1):43-66.
2. Marcus R and Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl 2007;(67):5-14.
3. Groves FD, Linet MS, Travis LB and Devesa SS. Cancer surveillance series: non- Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92(15):1240-51.
4. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89(11):3909-18.
5. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002-6.
6. Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield C D, Nissen NI, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003;21 (1):5-15.
7. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25(2 Suppl 2):11-6
8. Feugier P, Van Hoof A, Sebban C, Solal- Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-26.
9. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine cyclophosphamide mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low- Grade Lymphoma Study Group. Blood. 2004;104(10):3064-71.
10. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-7.
11. Herold M, Haas A, Srock S, Neser S, Al-Ali K H, Neubauer A, et al. Rituximab added to first-line mitoxantrone chlorambucil and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986-92.
12. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide doxorubicin vincristine and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low- Grade Lymphoma Study Group Blood. 2005;106(12):3725-32.
13. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide doxorubicin vincristine and prednisone significantly improves response and time to treatment failure but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984-92.
14. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III Study of R-CVP Compared With Cyclophosphamide Vincristine and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma. J Clin Oncol. 2008;26(28): 4579-86.
15. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol. 2006;7(5):379-91.
16. Salles G, Mounier N, de Guilbert S, Morschhauser F, Doyen C, Rossi JF, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112(13):4824-31.
17. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood. 2006;108(10):3295-301
18. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23(6):1088-95.
19. Hagenbeek A. Maintenance or Eradication of Residual Disease in Indolent Lymphoma: Where Do We Stand? J Clin Oncol. 2009; 27(10):1540-2.
20. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007;(2):86-95.
21. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006;(7):564-76.
22. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14(5):1561-70.
23. Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program. 2005;329-34.
24. Gong Q, Ou Q, Ye S, Lee W P, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174(2):817-26.
25. Smith MR. Rituximab (monoclonal anti- CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359-68.
26. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103(7): 2738-43.
27. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171(3):1581-7.
28. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101 (3):949-54.
29. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complementinduced cell death by rituximab depends on CD20-expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006;12(13): 4027-35.
30. Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)- induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol. 2005;139(3):439-46.
31. Teeling JL, French RR, Cragg MS, van den BJ, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793-800.
32. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1): 362-71.
33. Wang L, Abbasi F, Gaigalas AK, Vogt RF, Marti GE. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells. Cytometry B Clin Cytom. 2006;70 (6):410-5.
34. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol. 1992;40(4):259-63.
35. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of Bcell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98(12):3383-9.
36. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, et al. Safety and efficacy of ofatumumab a fully human monoclonal anti-CD20 antibody in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111(3):1094-100.
37. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, et al. First clinical use of ofatumumab a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I/II trial. Blood 2008;111(12):5486-95.
38. van Meerten T, Claessen MJ, Hagenbeek A, Ebeling SB. The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T-cells. Gene Ther. 2006;13(9):789-97.
39. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW. Complementmediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045-52.
40. Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol.1998;103(2): 335-42.
41. van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood. 2003;102(7): 2522-31.
42. Rozemuller H, Knaän-Shanzer S, Hagenbeek A, van Bloois L, Storm G, Martens AC. Enhanced engraftment of human cells in RAG2/gammac doubleknockout mice after treatment with CL2MDP liposomes. Exp Hematol. 2004;32 (11):1118-25.
43. Mutis T, van Rijn RS, Simonetti ER, Aarts- Riemens T, Emmelot ME, et al. Human regulatory T-cells control xenogeneic graft-versus- host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin Cancer Res. 2006;12(18): 5520-5.
44. Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008;181 (1):822-32.
45. Bleeker WK, Munk ME, Mackus WJ, van den Brakel JH, Pluyter M, Glennie MJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol. 2008;140(3):303-12.
46. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183(1):749-58.
47. Bindon CI, Hale G, Bruggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med. 1988;168(1):127-42.
48. Xia MQ, Hale G, Lifely MR, Ferguson MA, Campbell D, Packman L, Waldmann H. Structure of the CAMPATH-1 antigen a glycosylphosphatidylinositol- anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J. 1993;293 (Pt 3):633-40.
49. Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993;30(12):1089-96.
50. Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica. 2006;91(2):176-83.
51. Beum PV, Kennedy AD, Williams ME, Lindorfer MA and Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol. 2006;176(4):2600-9.
52. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003;102(10):3514-20.